On Thursday, Sept 21, 2023, the Endocrinologic Drugs Advisory Committee (EDAC) will discuss the safety and efficacy of ITCA 650 (exenatide in DUROS device), a drug-device combination product that is the subject of a new drug application (NDA) submitted by Intarcia Therapeutics, Inc. (Intarcia) (NDA 209053), for the proposed indication, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
Back to All Events
Earlier Event: September 13
Cardiovascular and Renal Drugs Advisory Committee
Later Event: September 27
Cellular, Tissue, and Gene Therapies Advisory Committee